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INTRODUCTION
The prevalence of prostate cancer is highest in Western co-
untries. In Korea, the frequency of prostate cancer has increased
recently, so that prostate cancer has become important in Korea
as well (1).
Interleukin-6 (IL-6) has been shown to have a central role
in host defense mechanisms by regulating immune responses,
homeostasis, and the induction of the acute phase reaction;
it also it plays an important role in the progression of prostate
cancer (2). Increased IL-6 levels have been shown to be asso-
ciated with prostate cancer progression and to the androgen-
independent phenotype (3). Many cancers such as melanoma,
renal cell carcinoma, Kaposis sarcoma, ovarian cancer, lym-
phoma, leukemia, and multiple myeloma have shown to be
activated by IL-6 (4, 5). The presence of IL-6 suggests a worse
prognosis in many carcinoma types. IL-6 can regulate the ex-
pression of androgen-responsive genes in an androgen-indepen-
dent manner and can induce androgen-independent growth
of androgen-dependent human prostate cancer cells (6).
Granulocyte macrophage colony-stimulating factor (GM-
CSF) is one of the hematopoietic colony-stimulating factors.
It is a glycoprotein that belongs to the family of human growth
factors and mediates promyelocyte differentiation and pro-
liferation, enhances the function of mature monocytes and
macrophages, inhibit osteoclasts, and activate the division of
osteoblasts (7). Several reports suggest that GM-CSF and its
receptors are present in many cancers. GM-CSF could be part
of a network of paracrine and autocrine loops that modulate
prostate carcinoma cell activity, and might be highly expressed
with advanced stages of prostate cancer where there is bone
and lymph node metastasis (8). However, the pathophysiolog-
ical functions of GM-CSF in normal as well in as cancer tissue
remain unclear. Moreover, immunological effects have result-
ed in the investigation of GM-CSF in a number of immuno-
therapeutic antitumor strategies for prostate cancer (9, 10).
In our previous study, the viability of the prostate cancer-3
(PC-3) cells has shown to be significantly increased by GM-
CSF administration in a dose-and time-dependent manner (11).
Therefore GM-CSF and IL-6 play an important role in the
development of prostate cancer as well as its growth and metas-
tasis. The aim of this study was to investigate the relation-
ship of GM-CSF and IL-6.
MATERIALS AND METHODS
Cell line
The hormone refractory PC-3 cell line was obtained from
94
Tae-Hyoung Kim, Seung-Young Oh,
Young-Sun Kim, Mi-Kyung Lee*,
Hwa-Su Kim
� , Soon-Chul Myung
Departments of Urology and Laboratory Medicine*,
College of Medicine, Chung-Ang University, Seoul;
Center for Disease Control & Prevention
� , Seoul, Korea
Address for correspondence
Soon Chul Myung, M.D.
Department of Urology, College of Medicine
Chung-Ang University, 224-1 Heukseok-dong,
Dongjak-gu, Seoul 156-755, Korea
Tel : +82.2-748-9715, Fax : +82.2-798-8577
E-mail : kthlmk@hanafos.com
*This research was supported by the Chung-Ang
University Grants in 2007.
J Korean Med Sci 2008; 23: 94-7
ISSN 1011-8934
DOI: 10.3346/jkms.2008.23.1.94
Copyright � The Korean Academy
of Medical Sciences
Granulocyte Macrophage Colony-Stimulating Factor May Modulate
the Post-transcription Pathway of Interleukin-6 Expression in
Prostate Carcinoma Cells
Interleukin-6 (IL-6) can stimulate a variety of tumors including prostatic carcinoma.
Research has recently shown that IL-6 may act to stimulate the progression of pro-
static cancer. To date, little research has been performed to better understand the
nature of granulocyte macrophage colony-stimulating factor (GM-CSF) and the expres-
sion of IL-6. The aim of this study was to evaluate the effects of GM-CSF on the expres-
sion of IL-6 in prostate cancer-3 (PC-3) cells. The bone-derived PC-3 cell line was
used in this study. Reverse transcription polymerase chain reaction (RT-PCR) and
real- time PCR were performed to detect IL-6 mRNA expression. The IL-6 protein
was measured by enzyme-linked immunosorbent assay (ELISA) after treatment with
hGM-CSF. Our data indicated that IL-6 mRNA expression did not increase after treat-
ment with hGM-CSF in comparison to the control group. However, the expression
of IL-6 protein was increased compared to the control group. GM-CSF may modu-
late the post-transcription pathway of IL-6 expression in prostate carcinoma cells.
Our data suggest that GM-CSF may have a role in IL-6-mediated development of
prostate cancer.
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the Korean cell line bank (Seoul, Korea). The basic cell wells
were filled with RPMI 1640 (Gibco, Carlsbad, NY, U.S.A.)
including 2% fetal bovine serum, L-glutamine, penicillin, st-
reptomycin, and the environment was maintained tempera-
ture 37℃and 5% CO2, room air 95%, and proper humidity.
RNA extraction and reverse transcription
The 5×105PC-3 cells were incubated in the basic cell wells.
After 24 hr of incubation, 50 ng/mL human GM-CSF (hGM-
CSF, Pierce Biotech. Inc., Rockford, IL, U.S.A.) was added to
the RPMI-1640 medium containing 2% fetal bovine serum.
Cultures of the PC-3 cells were incubated for 4, 8, 12, 24, and
48 hr at 37℃ in humid air with 5% CO2, and total RNA
was extracted using the RNeasy Mini Kit (QIAGEN Inc.,
Valencia, CA, U.S.A.) per the manufacturer’s directions. To
remove genomic DNA contamination, RNA samples were
treated with 2 units DNase I (Roche Diagnostic Corp., Indi-
anapolis, IN, U.S.A.) per 100  L of RNA at 37℃ for 1 hr.
RNA purity was determined by the A260/A280 ratio and quan-
tified via A260. Reverse transcription was performed in a total
volume of 40  L with Reverse Transcriptase AMV kit (Roche,
Penzberg, Germany) using 1  g of RNA, 4  L of 10×reac-
tion buffer (100 mM Tris, 500 mM KCl, pH 8.3), 5 mM
MgCl2, 1 mM dNTP mix (dATP, dCTP, dTTP, dGTP), 50
U RNase inhibitor, 20 U AMV reverse transcriptase, and 4
L of oligo-p (dT)15 primer. The reverse transcription reac-
tions were incubated at 25℃for 10 min and then at 42℃for
60 min followed by 99℃for 5 min to inactivate the reverse
transcriptase using GeneAmp PCR system 2400 (Applied
Biosystems, Foster city, CA, U.S.A.). The control samples were
incubated for 48 hr and underwent the same treatment except
for adding the hGM-CSF. 
Conventional PCR
Conventional polymerase chain reaction (PCR) was carried
out in 20  L volume containing 10 pM each primer (12) (Table
1), 10 mM Tris-Cl (pH 8.3), 2 mM MgCl2, and 200 mM
dNTP. PCR was performed with 30 amplification cycles using
the GeneAmp PCR system 2400 (Applied Biosystems), and
PCR products underwent electrophoresis on 2% agarose gels.
Real-time PCR
In order to optimize the real-time PCR conditions, and ver-
ify the specificity of the designed primer pairs, the optimal
primers and template concentrations were determined using
2×SYBR
� Green PCR Master Mix (Applied Biosystems)
and a melting curve analysis. Real-time PCR assays contained
12.5  L of 2×SYBR
� Green PCR Master Mix, 300 nM each
PCR primer, and 2  L of cDNA from the reverse transcrip-
tion step (unknown samples) or PCR amplicons from each
dilution (standard curve) in 25  L. Real-time PCR was per-
formed in the ABI PRISM
� 7000 (Applied Biosystems) start-
ing with 10 min of preincubation at 95℃, followed by 40
amplification cycles at 95℃ for 15 sec and 60℃ for 1 min
and melting curve analysis. Relative quantification of genes
was determined for each sample in three separate PCR reac-
tions using the same RNA preparation. The concentration of
each gene (IL-6 and glyceraldehyde 3-phosphate dehydroge-
nase [GAPDH]) was calculated by reference to the respective
standard curve with the aid of the ABI PRISM
� 7000 software.
Relative gene expression was calculated as a ratio of the target
gene (IL-6) concentration to housekeeping gene (GAPDH)
concentration.
IL-6 protein using Enzyme-Linked Immunosorbent Assay
(ELISA)
The 5×105 PC-3 cells were incubated in the basic 6 wells.
After 24 hr of incubation, 50 ng/mL hGM-CSF was added
to the RPMI-1640 wells including 2% fetal bovine serum.
After 4, 8, 12, 24, and 48 hr incubation, we measured IL-6
proteins with 6 samples, respectively, using an ELISA kit
(Amersham Biosciences, Uppsala, Sweden) in culture media.
Six control samples underwent the same treatment except for
adding the hGM-CSF. After 48 hr incubation, IL-6 protein
manifestation was measured using ELISA.
Statistical analysis
The results were expressed as the mean±standard deviation
(SD) of experiments. Data were analyzed using Wilcoxon two-
sample t-test for comparisons. A p value less than 0.05 was
considered significant.
RESULTS
IL-6 mRNA expression after hGM-CSF treatment by
conventional reverse transcription-PCR (RT-PCR)
IL-6 mRNA expression was gradually increased in accordance
with time in control groups. After hGM-CSF treatment, IL-
6 mRNA expression was increased at 4 hr, decreased until 12
hr, and then increased at 24 and 48 hr (Fig. 1).
IL-6, interleukin-6; GAPDH, glyceraldehyde-3-phosphate dehydroge-
nase.
Gene Primer sequence Product size
IL-6 Sense 5′ -AAATTCGGTACATCCTCGAC-3′ 295 bp
Antisense 5′ -CAGGAACTGGATCAGGACTT-3′
GAPDH Sense 5′ -GAAGGTGAAGGTCGGAGTC-3′ 228 bp
Antisense 5′ -GAAGATGGTGATGGGATTTC-3′
Table 1. Primer sequences used for reverse transcription poly-
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IL-6 mRNA expression after hGM-CSF treatment by
real-time PCR
Relative gene expression was calculated as the ratio of the
target gene (IL-6) concentration to the housekeeping gene
(GAPDH) concentration. The expression of IL-6 mRNA was
139.33±24.55 in the control group. After hGM-CSF treat-
ment, the expression of IL-6 mRNA incubated at 4, 8, 12, 24,
48 hr was 134.38±39.23, 81.86±43.12, 93.15±3.11, 124
±23.42, and 129.43±43.37, respectively (Fig. 2).
IL-6 protein expression using ELISA
The IL-6 level represents the mean and standard deviation
in each of the 6 wells incubated for a different period of time.
The concentration of IL-6 was 23.23±4.00 pg/mL in the con-
trol group. The IL-6 concentrations, incubated at 4, 8, 12, 24,
and 48 hr were 47.40±2.97, 52.19±2.18, 53.65±8.45,
54.06±6.98, and 55.52±9.28 pg/mL, respectively (Fig. 3).
The IL-6 protein expression increased after 4 hr of incubation
compared to the control group (p<0.01).
DISCUSSION
In this study, we demonstrated the relationship of GM-CSF
with IL-6 in the PC-3 cells. Many reports have shown that GM-
CSF and its receptors are expressed in normal tissue, breast can-
cer, ovarian cancer, bladder cancer, pancreas cancer, small cell
cancer of the lung, stomach cancer, and melanoma (13). In pro-
state cancer, GM-CSF and its receptors are also expressed and
may be part of a network of paracrine and autocrine loops that
modulate prostate carcinoma cell activity (14). GM-CSF also
promotes the differentiation and survival of dendritic cells (15).
GM-CSF is presumed to stimulate dendritic cells to uptake
and process antigens, leading to cross-priming of antigen spe-
cific T cells and an antigen T-cell response. These pleiotropic
immunological effects have resulted in the investigation of
GM-CSF in a number of immunotherapeutic antitumor strate-
gies for prostate cancer (9, 10). Whether or not therapeutical-
ly administered hematopoietic growth factors can stimulate
nonhematopoietic cell growth, including solid tumor cells,
has remained a controversial issue.
IL-6 is implicated in the regulation of a variety of cellular
events in tumor cells. IL-6 exerts different effects on prolifer-
ation and apoptosis, and stimulates angiogenesis through the
regulation of vascular endothelial growth factor (16). IL-6 is
produced in many organs, but its serum level is very low with
appropriate modulation in healthy people (17, 18). However,
the IL-6 level is significantly increased in metastatic prostate
cancer and is strongly related to the serum prostate-specific
antigen (PSA) level (19). Some reports have suggested that
IL-6 is increased in the hormone refractory phase of prostate
cancer when compared to chronic prostatitis and benign pro-
static hyperplasia (BPH) (20). Therefore, IL-6 is a potential
mediator associated with prostate cancer morbidity and a mark-
er of disease activity for predictive clinical testing. IL-6 recep-
tor mRNA has been identified in all prostate cancer cell lines,
but not in epithelia or stromal cells extracted from BPH (21).
Okamoto et al. reported that IL-6 functions as a paracrine gro-
wth factor for human LNCaP androgen-sensitive prostate can-
cer cells and as an autocrine growth factor for human DU-145
Fig. 2. Time course of the IL-6 mRNA expression by real-time PCR.
The PC-3 cells were treated with hGM-CSF for the indicated times.
The control samples were incubated for 48 hr. The IL-6 mRNA ex-
pression was not increased at specific incubation time.
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Fig. 3. The average IL-6 concentration (ng/mL) and their standard
deviation by the incubations period as determined by ELISA. The
control samples were incubated for 48 hr. The IL-6 protein expression
was significantly increased at 4, 8, 12, 24, and 48 hr after hGM-
CSF treatment compared with the control group. *p<0.01.
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Fig. 1. Time course of the IL-6 mRNA expression by conventional
RT-PCR in PC-3 cells. IL-6 mRNA expression was gradually increas-
ed in control groups (lanes 1-5). IL-6 mRNA expression was incr-
eased at 4 hr, decreased until 12 hr, and then increased at 24 and
48 hr after hGM-CSF treatment (lanes 6-10). M, molecular size mark-
er; 1-5, control groups; 6-10, hGM-CSF-treated groups.
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and PC-3 androgen-insensitive prostate cancer cells (20). How-
ever, IL-6 has no function in the stimulation of epithelia derived
from BPH (22). The stimulatory and inhibitory effects of IL-
6 in the same cell line are not always consistent. Results of
numerous studies have demonstrated the pleiotropic nature
of IL-6 action in prostate carcinoma cells. Charyulu and Lopez
(23) demonstrated for the first time that GM-CSF plays an
important role in increased IL-6 production by B-lymphocytes
and that this effect, irrespective of the upregulation of tumor
necrotic factor- by GM-CSF, appears to depend on the actual
presence of GM-CSF in the microenvironment. They conclud-
ed that GM-CSF might function as a direct activator or induc-
er of IL-6 production. In this study, IL-6 mRNA expression
was not increased after hGM- CSF treatment at specific incu-
bation times in hormone-refractory prostate cancer cells in com-
parison with the control group when measured by convention-
al and real-time PCR. However, the IL-6 protein concentra-
tion was increased after hGM-CSF treatment when measured
by ELISA. Therefore, GM-CSF may modulate the post-tran-
scription pathway of IL-6 expression in prostate carcinoma
cells. Collectively, our results suggest that GM-CSF may have
a more complex role in IL-6-mediated development of prostate
cancer. It was postulated that GM-CSF might induce over-
expression of IL-6 in the extracellular pathway in addition to
the known intracellular pathway. Our data cannot exactly ex-
plain the reason for this discrepancy. Further studies to inves-
tigate the relationship of IL-6 and GM-CSF in prostate can-
cer are needed. 
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